Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Akorn, Inc.
Akorn Reports First Quarter 2009 Financial Results
May 27th, 2009
Akorn, Inc. (NASDAQ: AKRX) a specialty pharmaceutical company, reported on financial results for the first quarter ended March 31, 2009. Total revenue for the first quarter 2009 was $22.0 million, versus $14.5 million in the first quarter 2008, representing an increase of approximately 52%. The revenue increase was driven by higher Td Vaccine sales, which totaled $10.7 million. Gross profit for the first quarter 2009 was $5.4 million as compared to $3.7 million in the first quarter 2008, an increase of 43%. The increase in first quarter 2009 gross profit is primarily due to the sale of Td Vaccines, which contributed approximately $3.4 million. Gross margin for the first...
Source: Vaccine Weekly (2009-05-27)
|
